Total Payments
$2.5M
2024 Payments
$372,352
Companies
42
Transactions
3,199
Medicare Patients
335
Medicare Billing
$325,708
Payment Breakdown by Category
Other$1.6M (66.1%)
Travel$440,603 (17.8%)
Consulting$299,335 (12.1%)
Food & Beverage$83,098 (3.4%)
Research$14,678 (0.6%)
Education$877.35 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 593 | 59.2% |
| Travel and Lodging | $440,603 | 1,235 | 17.8% |
| Consulting Fee | $299,335 | 130 | 12.1% |
| Honoraria | $165,890 | 93 | 6.7% |
| Food and Beverage | $83,098 | 1,109 | 3.4% |
| Unspecified | $14,678 | 25 | 0.6% |
| Charitable Contribution | $5,000 | 1 | 0.2% |
| Education | $877.35 | 11 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $250.00 | 1 | 0.0% |
| Entertainment | $45.03 | 1 | 0.0% |
Payments by Type
General
$2.5M
3,174 transactions
Research
$14,678
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $444,227 | 507 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $363,649 | 585 | $0 (2024) |
| GENZYME CORPORATION | $336,673 | 360 | $0 (2024) |
| Amgen Inc. | $305,862 | 366 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $266,231 | 256 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $150,319 | 267 | $0 (2021) |
| Vifor Pharma, Inc. | $123,591 | 142 | $0 (2024) |
| Travere Therapeutics, Inc. | $68,068 | 142 | $0 (2024) |
| Baxter Healthcare | $65,409 | 101 | $0 (2024) |
| GlaxoSmithKline, LLC. | $59,114 | 70 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $372,352 | 437 | GENZYME CORPORATION ($89,634) |
| 2023 | $322,807 | 416 | Fresenius USA Marketing, Inc. ($62,116) |
| 2022 | $337,065 | 425 | Bayer HealthCare Pharmaceuticals Inc. ($95,899) |
| 2021 | $291,173 | 321 | AstraZeneca Pharmaceuticals LP ($141,852) |
| 2020 | $203,438 | 256 | AstraZeneca Pharmaceuticals LP ($69,415) |
| 2019 | $337,104 | 544 | AstraZeneca Pharmaceuticals LP ($84,235) |
| 2018 | $323,798 | 412 | GENZYME CORPORATION ($85,199) |
| 2017 | $285,523 | 388 | Amgen Inc. ($85,848) |
All Payment Transactions
3,199 individual payment records from CMS Open Payments — Page 1 of 128
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $112.09 | General |
| 12/27/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Travel and Lodging | Cash or cash equivalent | $89.21 | General |
| Category: Nephrology | ||||||
| 12/27/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $10.03 | General |
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,570.00 | General |
| Category: Cardio-renal | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,614.00 | General |
| Category: Cardio-renal | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,614.00 | General |
| Category: Cardio-renal | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,614.00 | General |
| Category: Cardio-renal | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,971.00 | General |
| Category: Cardio-renal | ||||||
| 12/19/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Travel and Lodging | Cash or cash equivalent | $134.26 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $126.02 | General |
| 12/19/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $66.16 | General |
| 12/19/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| Category: Diabetes | ||||||
| 12/19/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | Cash or cash equivalent | $28.45 | General |
| Category: Diabetes | ||||||
| 12/18/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Consulting Fee | Cash or cash equivalent | $8,085.00 | General |
| Category: Nephrology | ||||||
| 12/16/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 12/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $1,323.92 | General |
| Category: Cardio-renal | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $73.11 | General |
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $97.78 | General |
| Category: Cardio-renal | ||||||
| 12/11/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| 12/11/2024 | Travere Therapeutics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 12/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $121.85 | General |
| Category: Cardio-renal | ||||||
| 12/11/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $56.37 | General |
| 12/11/2024 | Travere Therapeutics, Inc. | — | Travel and Lodging | Cash or cash equivalent | $36.93 | General |
| 12/11/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $23.23 | General |
| 12/11/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $12.64 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm | Amgen Inc. | $11,263 | 1 |
| A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | GlaxoSmithKline, LLC. | $2,886 | 21 |
| A Phase 3 randomized, open label sponsor blind , active controlled, parallel group, multi center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to re | GlaxoSmithKline, LLC. | $231.62 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 43 | 141 | $156,336 | $28,214 |
| 2022 | 4 | 85 | 332 | $382,622 | $85,201 |
| 2021 | 4 | 81 | 386 | $442,434 | $101,692 |
| 2020 | 5 | 126 | 541 | $568,165 | $110,601 |
Total Patients
335
Total Services
1,400
Medicare Billing
$325,708
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 13 | 83 | $106,572 | $25,283 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 30 | 58 | $49,764 | $2,930 | 5.9% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 22 | 172 | $220,848 | $53,546 | 24.2% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 15 | 88 | $95,268 | $22,185 | 23.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 18 | 22 | $23,606 | $5,689 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 50 | $42,900 | $3,781 | 8.8% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 21 | 183 | $234,972 | $57,459 | 24.5% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2021 | 20 | 126 | $134,946 | $32,698 | 24.2% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 19 | 30 | $32,190 | $7,834 | 24.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 21 | 47 | $40,326 | $3,701 | 9.2% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 30 | 234 | $288,990 | $58,346 | 20.2% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2020 | 22 | 171 | $176,985 | $35,581 | 20.1% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2020 | 22 | 44 | $45,760 | $9,155 | 20.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 29 | 57 | $36,480 | $5,266 | 14.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 23 | 35 | $19,950 | $2,252 | 11.3% |
About Dr. Anjay Rastogi, MD
Dr. Anjay Rastogi, MD is a Nephrology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003836602.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anjay Rastogi, MD has received a total of $2.5M in payments from pharmaceutical and medical device companies, with $372,352 received in 2024. These payments were reported across 3,199 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Rastogi has provided services to 335 Medicare beneficiaries, totaling 1,400 services with total Medicare billing of $325,708. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Internal Medicine
- Location Los Angeles, CA
- Active Since 07/19/2006
- Last Updated 07/15/2008
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1003836602
Products in Payments
- Velphoro (Drug) $318,471
- LOKELMA (Drug) $297,982
- Kerendia (Drug) $265,711
- Parsabiv (Biological) $225,474
- FABRAZYME (Drug) $152,376
- FABRAZYME (Biological) $140,938
- JYNARQUE (Drug) $138,196
- Veltassa (Drug) $114,668
- FARXIGA (Drug) $84,800
- JARDIANCE (Drug) $77,757
- Parsabiv (Drug) $61,152
- JESDUVROQ (Drug) $38,183
- Renal - PD (Device) $30,285
- NO PRODUCT DISCUSSED (Drug) $20,989
- XARELTO (Drug) $16,216
- Velophoro (Drug) $16,101
- KORSUVA (Drug) $14,388
- TAVNEOS (Drug) $10,808
- DISEASE STATE (Drug) $10,435
- Fabhalta (Drug) $9,704
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Los Angeles
Dr. Suphamai Bunnapradist, M.d, M.D
Nephrology — Payments: $462,290
Nephrology $462,290
Dr. Tariq Shah, M.d, M.D
Nephrology — Payments: $342,153
Nephrology $342,153
Victoria Kumar, Md, MD
Nephrology — Payments: $319,042
Nephrology $319,042
Victor Carabello, M.d, M.D
Nephrology — Payments: $277,340
Nephrology $277,340
Susanne Nicholas, Md, MD
Nephrology — Payments: $142,466
Nephrology $142,466
Allen Nissenson, Md, MD
Nephrology — Payments: $101,471
Nephrology $101,471